Obstructive sleep apnea complicates 65% post-coronary revascularization patients versus 38% non-intervened controls, with a 2025 Sleep and Breathing systematic review/meta-analysis of 12 studies (4,346 total) revealing OR 2.84 and AHI +12.4demanding universal screening to curb MACE. This synthesis guides post-PCI/CABG protocols.
Revascularisation Context: CABG vs PCI Landscape
Coronary artery bypass grafting (CABG) reroutes via grafts (LIMA 90% patency 10yr); percutaneous coronary intervention (PCI) stents plaque (DES 85% restenosis-free 5yr). Annual 1M U.S. procedures; 30-day mortality 2% CABG, 1% PCI. OSA prevalence pre-op 40-60%; post-op spikes from anesthesia slackening pharynx, opioids suppressing drive, supine positioning, fluid shifts narrowing airways.
Systematic Review Methodology Excellence
Ajosenpää et al. PRISMA-compliant searched MEDLINE/Embase/CENTRAL to October 2024; 12 eligible (8 CABG-focused, 4 PCI/mixed), observational cohorts minimum 20pts PSG/HSAT confirmed OSA (AHI≥5). Random-effects DerSimonian-Laird pooled OR prevalence, MD severity; I²<50% most, GRADE moderate (downgraded indirectness); subgroup timing (pre/early/late post-op), intervention type; funnel no asymmetry.
Prevalence Disparity: OR 2.84 Post-Revascularization
Pooled OSA 65.2% (1,601/2,456 post) vs 37.8% (715/1,890 no-intervention; OR 2.84 95% CI 2.12-3.81, I²=47%, 10 studies). CABG OR 3.21 (2.34-4.40, I²=38%, 6 studies); PCI 2.45 (1.78-3.37, I²=52%). Severe (>30 AHI) OR 4.12 (2.89-5.87). Timing: early post-op (<30d) OR 3.45, late (>90d) 2.56.
| Subgroup | Prevalence Post % (n) | OR (95% CI) | I² | Studies |
| All Post | 65.2 (1601/2456) | 2.84 (2.12-3.81) | 47 | 10 |
| CABG | 71.8 (1123/1564) | 3.21 (2.34-4.40) | 38 | 6 |
| PCI | 52.4 (478/912) | 2.45 (1.78-3.37) | 52 | 4 |
| Severe OSA | 27.9 (412/1477) | 4.12 (2.89-5.87) | 29 | 7 |
Severity Escalation: Quantitative Burden
AHI MD +12.4 events/h (95% CI 8.2-16.6, I²=72%, 9 studies); CABG +15.8, PCI +9.2. ODI +14.7, arousal index +8.3/h, min SaO2 -3.9%. Supine bias post-CABG +18 AHI. GRADE low heterogeneity bias.
Pathophysiological Drivers Post-Intervention
Acute: anesthetics (propofol pharyngeal dilator -30%), narcotics respiratory depression, intubation edema, pleural effusions. Chronic: CAD visceral fat predisposes, revascularization inflammation (CRP +50% week 1), beta-blockers central apneas. Supine hospital positioning doubles AHI transient.
Prognostic Ramifications: MACE Amplifier
Embedded cohorts: untreated OSA doubles restenosis (HR 2.1), MACE 2.3, mortality 1.8. Severe post-CABG graft failure +42%. APAP halves events pilot data.
Screening Imperatives: Protocol Standardization
Universal post-op: STOP-BANG ≥3 (sens 92%) → HSAT (portable Type 3, AHI corr 0.89 PSG). Timing: discharge-week 4 peak severity. Threshold AHI≥15 auto-titrate APAP.
| Tool | Sensitivity | Specificity | Cost |
| STOP-BANG | 92% | 47% | $0 |
| Berlin | 86% | 55% | $0 |
| HSAT Type 3 | 89% | 78% | $200 |
| PSG Level 1 | 95% | 90% | $1,200 |
Therapeutic Escalation: APAP Perioperative
Inpatient split-night titration feasibility 78%; ambulatory APAP AHI -65%, adherence 62% 6mo. ASV central components post-CABG. Surgery delay elective if severe undiagnosed.
Cost-Utility and Policy Levers
Screening $250/pt prevents $18k MACE/patient; QALY $11k. Bundle PCI codes reimburse HSAT. Global: ESC mandates OSA screen STEMI.
Limitations: Observational Confounds
Heterogeneity intervention eras; PSG variability; no serial pre-post matched. GRADE moderate prevalence, low severity.
Future: Prospective Serial Cohorts Needed
Pre/post-op PSG pairs; wearables validation; pharmaco-prophylaxis (acetazolamide).
Clinical Checklist: Revascularization Red Flags
BMI>30 + snoring? STOP day 1; apneas witnessed? HSAT stat.
FAQ
OSA odds post-revascularization?
OR 2.84 vs no-intervention; CABG 3.21.
AHI change post-CABG specifically?
+15.8 events/h; supine dominant.
Screening tool post-PCI?
STOP-BANG ≥3 → HSAT; sens/spec optimal.
APAP halves MACE post-op?
Pilot yes; adherence key 62% 6mo.
Timing worst severity?
Week 1-4 discharge; screen then.
